Context Therapeutics Future Growth
Future criteria checks 0/6
Context Therapeutics's earnings are forecast to decline at 21.8% per annum while its annual revenue is expected to grow at 79.3% per year. EPS is expected to grow by 4.2% per annum.
Key information
-21.8%
Earnings growth rate
4.2%
EPS growth rate
| Pharmaceuticals earnings growth | 21.1% |
| Revenue growth rate | 79.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 21 Mar 2024 |
Recent future growth updates
Recent updates
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27
Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
Jun 05Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Sep 27We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Sep 15Context Therapeutics GAAP EPS of -$0.25 in-line
Aug 11Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Aug 02Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
May 28Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Nov 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -46 | -52 | N/A | 2 |
| 12/31/2025 | N/A | -17 | -41 | N/A | 3 |
| 12/31/2024 | N/A | -29 | -32 | N/A | 3 |
| 12/31/2023 | N/A | -24 | -21 | -21 | N/A |
| 9/30/2023 | N/A | -21 | -18 | -18 | N/A |
| 6/30/2023 | N/A | -19 | -18 | -17 | N/A |
| 3/31/2023 | N/A | -18 | -16 | -15 | N/A |
| 12/31/2022 | N/A | -15 | -14 | -14 | N/A |
| 9/30/2022 | N/A | -14 | -15 | -15 | N/A |
| 6/30/2022 | N/A | -12 | -12 | -12 | N/A |
| 3/31/2022 | N/A | -13 | -11 | -11 | N/A |
| 12/31/2021 | N/A | -10 | -9 | -9 | N/A |
| 9/30/2021 | N/A | -8 | -4 | -4 | N/A |
| 6/30/2021 | N/A | -7 | -5 | -4 | N/A |
| 3/31/2021 | N/A | -1 | -3 | -3 | N/A |
| 12/31/2020 | N/A | 1 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNTX is forecast to have no revenue next year.
High Growth Revenue: CNTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNTX's Return on Equity is forecast to be high in 3 years time